Cargando…
Dalbavancin: novel candidate for COVID-19 treatment
Autores principales: | Hoffmann, Markus, Jin, Yeonhwa, Pöhlmann, Stefan |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Nature Singapore
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7816554/ https://www.ncbi.nlm.nih.gov/pubmed/33473156 http://dx.doi.org/10.1038/s41422-020-00459-5 |
Ejemplares similares
-
Publisher Correction: Dalbavancin: novel candidate for COVID-19 treatment
por: Hoffmann, Markus, et al.
Publicado: (2022) -
Novel SARS-CoV-2 receptors: ASGR1 and KREMEN1
por: Hoffmann, Markus, et al.
Publicado: (2021) -
Mutation D614G increases SARS-CoV-2 transmission
por: Arora, Prerna, et al.
Publicado: (2021) -
Omicron: Master of immune evasion maintains robust ACE2 binding
por: Hoffmann, Markus, et al.
Publicado: (2022) -
Azvudine (FNC): a promising clinical candidate for COVID-19 treatment
por: Yu, Bin, et al.
Publicado: (2020)